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http:WHAT THIS PAPER ADDS
There are very few validated scores for assessing mortality risk in peripheral arterial occlusive disease (PAOD)
patients. The present study uses the COhorte de Patients ARTériopathes (COPART) Risk Score in PAOD patients
suffering from intermittent claudication with regard to their mortality rate in a long-term observation study. The
COPART score is a suitable tool to highlight patients with a high all-cause and cardiovascular mortality risk.Objectives: The COhorte de Patients ARTériopathes (COPART) Risk Score is a risk score assessing the 1 year
outcome of patients who received inpatient treatment because of their peripheral arterial occlusive disease
(PAOD). The COPART Risk Score consists of six variables each of which is allocated a different number of points
(age, history of myocardial infarction, C-reactive protein, ankleebrachial index, estimated glomerular ﬁltration
rate, medication with antiplatelet agents, statins and renineangiotensin system inhibitors).
Methods: 129 consecutive claudicants were included in a prospective trial with an average follow up of 8.8 (
0.7) years. All patients were hospitalized for their ﬁrst endovascular procedure to the pelvic and/or
femoropopliteal arteries. The endpoints were all cause mortality and cardiovascular (CV) death. The COPART Risk
Score was calculated for the three patient cohorts (low risk: 52 patients [40.3%]; medium risk: 41 patients
[31.8%]; high risk: 36 patients [27.9%]).
Results: During the follow up period 23.1% (n ¼ 12) of patients in the low risk group, 34.1% (n ¼ 14) of patients
in the medium risk group, and 63.9% (n ¼ 23) of patients in the high risk group died. CV death occurred in 11.5%
in the low, 22.0% in the medium, and 41.7% in the high risk groups. The three groups differed signiﬁcantly with
regard to all cause and CV mortality (p < .0001 and p ¼ .001).
Conclusions: The COPART Risk Score is a suitable instrument to predict long-term all cause and CV mortality in
claudicants preceding their ﬁrst peripheral intervention.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Chronic peripheral arterial occlusive disease (PAOD) as a
manifestation of atherosclerosis in the pelvic and leg ar-
teries has become common enough to be regarded as a
pandemic.1,2 Patients predominantly die as a consequence
of atherosclerotic events of the cerebral and coronary
vessels.3
There are very few validated scores assessing the mor-
tality risk of PAOD patients.4,5 The COhorte de Patients
ARTériopathes (COPART) Risk Score is a well deﬁned andresponding author. Division of Angiology, Medical University Graz,
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//dx.doi.org/10.1016/j.ejvs.2015.04.009simple to calculate score developed in France that assesses
the mortality and CV event risk (low risk [LR], medium risk
[MR], high risk [HR], very high risk [VHR]) of patients who
had to receive inpatient treatment for their symptomatic
PAOD during a 1 year follow up period.6 Unlike other
scoring systems available for PAOD patients, during the
creation of this score only patients who had to be hospi-
talized because of the severity of their disease were
included. The COPART Risk Score consists of six variables
(age, history of myocardial infarction, C-reactive protein
[CRP], ankleebrachial index [ABI], estimated glomerular
ﬁltration rate [eGFR], medication with antiplatelet agents,
statins, and renineangiotensin system [RAS] inhibitors),
which are assigned a variable number of points.7
As claudicants have a 1 year mortality of 3%, observa-
tions over a longer period of time are of particular interest.8
Therefore the COPART Risk Score for prediction of CV
events and long-term mortality in claudicants prior to their
ﬁrst endovascular procedure were evaluated. The decision
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because intermittent claudication is the most prominent
lead symptom of the disease. Additionally, the presence of
this symptom is frequently the point in time when the ﬁrst
contact with a vascular specialist takes place. Furthermore,
it was believed it to be of interest to investigate how
applicable this scoring system is in a highly selected patient
cohort (Rutherford Stages 2 and 3).MATERIALS AND METHODS
Study design and patient cohort
Between March 2002 and November 2004, 129 consecutive
patients were included in a prospective observational study
of death or a CV event (myocardial infarction, stroke,
amputation). Patients presented at the outpatient clinic of
the Division of Angiology, Graz with intermittent claudica-
tion (Rutherford Stages 2e3), and those who had to un-
dergo their ﬁrst endovascular procedure of the pelvic and/
or femoropopliteal arteries (including the P3 segment of the
popliteal artery) were included in this study. All in-
terventions were carried out via the common femoral artery
by either antegrade or retrograde access. As intermittent
claudication is not an indication for endovascular recanali-
zation of below knee (BTK) arteries, these patients were not
included in this series.9 If there was no therapy with anti-
platelet agents preceding the endovascular intervention,
therapy with acetylsalicylic acid (ASA) 100 mg per day was
started. Patients who already received other antiplatelet
agents prior to the endovascular intervention because of
their known coronary artery disease (CAD) were not
changed to ASA.
Patients who were suffering from unstable angina pec-
toris or the consequences of a stroke at the time of
enrollment were excluded. Furthermore, patients with
malignant arterial hypertension, decompensated heart
failure, life expectancy of less than a year, wound infections,
and contraindications to anticoagulants and/or antiplatelet
agents were also excluded. All patients gave their written
informed consent after being accurately informed about the
clinical trial.Data collection
The baseline characteristics of the patients were assessed
on the day of the endovascular intervention. All blood
samples were taken on the day before the intervention. This
also applied to ABI measurements. In total, four follow up
visits were conducted after 1, 3, 6, and 12 months. The
patients’ concomitant medication and the occurrence of CV
events were noted at each study visit. Between October
2010 and May 2011 the ﬁnal examination was undertaken.
In the course of the ﬁnal examination, the occurrence of CV
events was established. For this purpose, patients were
invited to an outpatient examination/survey, in which they
answered questions about their PAOD symptoms, medical
history, and current medication. Patients who could not
attend the examination were interviewed by phone usingthe same survey. If the patient had died or could not be
reached by phone, the primary care physician was con-
tacted. The required mortality and CV event data and cur-
rent medication (antiplatelet agents, coumarins, statins, and
antihypertensive drugs in particular) were collected. In a
ﬁnal step, data collection was completed by a review of all
medical ﬁles in all public Styrian hospitals including their
emergency rooms as well as divisions of pathology.
The study was approved by the Institutional Review
Board of the Medical University Graz, Austria (EK 23-038 ex
10/11).
COPART Risk Score
The COPART Risk Score was calculated using the following
parameters: age 75e84 years, þ 2 points; age  85, þ 3
points; history of myocardial infarction, þ 1 point; CRP 
70 mg/L, þ 2 points; ABI < 0.3, þ 2 points; ABI 0.3e0.49, þ
1.5 points; ABI  1.3, þ 2 points; eGFR, > 30e60 mL/min/
1.73 m2, þ 1 point; eGFR  30 mL/min/1.73 m2, þ 1.5
points; medication with antiplatelet agents and statins and
RAS inhibitors, e 1.5 points. Medication assessment was
made at the end of the follow up period.
Unlike the original COPART Risk Score with a division into
four groups (LR:  0 points, MR: 0.5e2 points, HR: 2.5e4
points, VHR:  4.5 points), the present study only distin-
guished three groups: LR ( 0 points), MR (0.5e2 points),
HR ( 2.5 points). These groupings were chosen because no
therapeutic consequences of the long-term inﬂuence of the
prognosis between HR and VHR patients were to be ex-
pected in clinical practice. Moreover, risk stratiﬁcation in LR,
MR, HR has been a reliable method for other medical
conditions.10,11 The division into only three risk groups was
also chosen because a VHR group would have consisted of
only eight patients, and consequently a statistically relevant
comparison could not have been drawn.
Statistics
For continuous variables, patient characteristics were
described as mean ( standard deviation). Skewed data
were expressed as median and interquartile range. Cate-
gorical variables were expressed as frequency and per-
centages. The normal distribution was examined via
KolmogoroveSmirnov and ShapiroeWilk test. For para-
metric distribution the three groups were compared by
analysis of variance (ANOVA). For non-parametric data, a
KruskaleWallis test was used. A Jonckheere Terpstra test
was used for the comparison of the COPART Risk Score
variables among the three groups and for trend statistics.
Survival analysis was assessed by KaplaneMeier curves and
Log-rank statistics. Statistical signiﬁcance was set at p < .05.
Statistical analyses were performed using SPSS version 20.0.
RESULTS
129 patients were included in the study. The majority of
patients were male (n ¼ 92; 71.3%). At the time of
enrollment the median age was 66 years (min. 39; max. 86),
and the average body mass index (BMI) was 26.2 ( 3.2)
Table 2. Procedural details.
Revascularization, n (%)
PTA 100 (77.5)
PTA þ stent 29 (22.5)
Lesions treated, n (%)
One 99 (76.7)
Two 25 (19.4)
Three 5 (3.9)
Treated vessels, n (%)
Iliac artery 30 (23.2)
Common femoral artery 0 (0)
Superﬁcial femoral artery 81 (62.8)
96 G. Hackl et al.kg/m2. The average follow up was 8.8 years ( 0.7). Patient
characteristics are shown in Table 1.
Procedural details are shown in Table 2.
The median COPART Risk Score was 1 point. Fifty two
patients (40.3%) were assigned to the LR group, 41 patients
(31.8%) to the MR, and 36 patients (27.9%) to the HR
group. The distribution in relation to the variables and a
comparison of the variables among the three groups is
shown in Table 3. CRP and medication with antiplatelet
agents, statins and RAS inhibitors were not signiﬁcantly
different among the three groups.Table 1. Patient characteristics.
n 129
Men, n (%) 92 (71.3)
Age (yrs), median
(25the75th percentile)
66 (60e76)
BMI kg/m2, mean
( standard derivation)
26.2 ( 3.2)
Observation time years,
mean ( standard derivation)
8.8 ( 0.7)
Previous history, n (%)
Myocardial infarction 12 (9.3)
Cerebrovascular disease
(stroke, TIA)
9 (7)
Diabetes mellitus 40 (31)
Arterial hypertension 101 (78.3)
Smoking 96 (74.4)
Current 52 (40.3)
Ex 44 (34.1)
Hypercholesterolaemia 67 (51.9)
Kidney function
eGFR mL/min/1.73 m2, median
(25the75th percentile)
64 (51e85.5)
Creatinine mg/dL, median
(25the75th percentile)
1.1 (1.0e1.3)
ABI, median (25the75th percentile) 0.68 (0.55e0.89)
Drug therapies at discharge, n (%)
Antiplatelet agents 113 (87.6)
Beta blockers 36 (27.9)
ACE inhibitors or ARBs 71 (55)
Statins 58 (45)
Hemoglobin g/dL, median
(25the75th percentile)
14.05 (13e15.1)
Platelets g/L, median
(25the75th percentile)
237 (198e272)
CRP mg/L, median
(25the75th percentile)
4 (3e9.5)
Lipids mg/dL, median
(25the75th percentile)
LDL 118 (94.5e148)
HDL 47 (40e59.5)
Triglycerides 141 (102e195)
Lipoprotein (a) 12 (9.5e47.1)
HbA1c %, median (25the75th percentile) 5.8 (5.4e6.4)
BMI ¼ body mass index; TIA ¼ transient ischemic attack;
eGFR ¼ estimated glomerular ﬁltration rate; ABI ¼ ankle
brachial index; ACE ¼ angiotensin converting enzyme inhibitors;
ARB ¼ angiotensin receptor blockers; CRP ¼ C-reactive protein;
LDL ¼ low density lipoproteins; HDL ¼ high density lipoprotein;
HbA1c ¼ hemoglobin A1c.
Popliteal artery 18 (14.0)
Infrapopliteal arteries 0 (0)
Median stenosis treated %
(25the75th percentile)
85 (80e95)
PTA ¼ percutaneous transluminal angioplasty.During the follow up period, 23 patients (17.8%) suffered
myocardial infarction, 22 patients (17.1%) had a stroke, and
14 patients (10.9%) underwent amputation of the initially
treated lower extremity. The average time to myocardial
infarction was 42.3  22.3 months. The average time to
stroke was 48.7  28.6 months. The three risk groups
differed signiﬁcantly with regards to CV events (p ¼ .035).
Fig. 1 shows the comparison of CV events among the three
groups.
Forty nine patients (38%) died during the observation
period, and 30 (23.3%) suffered CV death. There were no
deaths within 30 days of the procedure. The average sur-
vival was 47.8  25.5 months. In the LR group, 23.1%
(n ¼ 12) had died by the end of follow up, 11.5% due to CV
disease (mean survival 96.7  4.1 months). In the MR group
34.1% (n ¼ 14) died during follow up (mean survivalTable 3. Scoring model for each variable.
Variable Frequency,
n (%)
p between
the groups*
Age
75e84 years (þ 2 points) 37 (28.7) 0.0001
 85 (þ 3 points) 2 (1.6) 0.074
History of myocardial
infarction (þ 1 point)
12 (9.3) 0.048
CRP  70 mg/L (þ 2 points) 2 (1.6) 0.5
ABI
< 0.3 (þ 2 points) 6 (4.7) 0.007
0.3e0.49 (þ 1.5 points) 15 (11.6) 0.003
 1.3 þ (2 points) 13 (10.1) 0.008
eGFR
30e60 mL/min/1.73 m2
(þ 1 point)
49 (38.0) 0.0001
 30 mL/min/1.73 m2
(þ 1.5 points)
6 (4.7) 0.007
Medication with antiplatelet
agents, statins and RAS inhibitors
during follow up (e 1.5 points)
24 (18.6) 0.2
CRP ¼ C-reactive protein; ABI ¼ ankleebrachial index;
eGFR ¼ estimated glomerular ﬁltration rate; RAS ¼ renin
angiotensin system.
*p values were calculated using the JonchkheereeTerpstra test.
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group patients died (mean survival 66.9  3.1 months). 22%
of MR group and 41.7% of HR group patients suffered a CV
death. The three groups differed signiﬁcantly with regards
to both, overall mortality and CV mortality (p < .0001 and
p ¼ .001). Figs. 2 and 3 show the chronological sequence
for the endpoints, overall survival and CV death, between
the three groups with KaplaneMeier curves.
Further analyses were done omitting the non-statistically
signiﬁcant variables CRP and medication between the three
groups. It was shown that the mortality results were not
substantially inﬂuenced by omitting these parameters
(overall mortality p ¼ .002; CV mortality p ¼ .006)
(Supplementary Fig. S1 and S2). Supplementary Fig. S3
shows the comparison between the original and the
modiﬁed (without CRP and medication) COPART Risk Score
using trend statistics. Supplementary Table S1 and
Supplementary Fig. S4eS6 show the re-calculated results on
the basis of “medication at discharge”. The results have not
changed signiﬁcantly.
As ABI is known to be an independent predictor of
mortality in PAOD patients, further analysis was carried out
and no signiﬁcant difference between survivors and non-
survivors was found (Supplementary Table S2 and
Supplementary Fig. S7).
DISCUSSION
The present study shows that the COPART score is also
suitable for the long-term prediction of death and CV eventsFigure 1. KaplaneMeier curve for cardiovasin claudicants. The adequate recording of raised and low-
ered ABI as risk parameters, in particular, seems to play a
signiﬁcant role. Resnick et al.12 have shown that both
decreased and increased ABI are important indicators for CV
death. Thus, the COPART risk score does not exclusively
determine the unfavorable prognosis of patients suffering
from critical limb ischemia. A raised ABI indicates the
presence of incompressible arteries due to medial sclerosis.
This implies the poor prognosis of diabetics and renal
impaired patients both of which are risk factors for medial
sclerosis.13e15
A history of myocardial infarction proved to be a signiﬁ-
cantly different predictive factor among the three risk
groups. This parameter is generally easy to determine and
seems to be meaningful with regards to the COPART Risk
Score even without further division of the previous
myocardial event into ST segment elevated or non-ST
elevated myocardial infarction, especially as it is known
that the long-term mortality risk is largely independent of
the ﬁrst time manifestation of the acute coronary syn-
drome.16 In the present cohort, mortality was especially
high in cases of myocardial infarction or stroke, as 30 out of
45 of these events were fatal.
Furthermore, the parameter age differed signiﬁcantly
among the comparison groups and therefore like other risk
scores, constitutes an essential and natural prognostic
factor.
Recently, numerous cellular and gene regulatory pro-
cesses were identiﬁed in patients suffering from renalcular events between the three groups.
Figure 2. KaplaneMeier curve for survival between the three groups.
Figure 3. KaplaneMeier curve for survival of cardiovascular death between the three groups.
98 G. Hackl et al.
COPART Risk Score Predicts Long-term Mortality 99insufﬁciency which lead, via increased calcium and phos-
phate serum levels, to the progression and development of
vascular calciﬁcation.17e21 Because of the calculation of
eGFR within the COPART Risk Score, this effect is also
detected in the present cohort.
Chronic increases in CRP are well known in the context of
atherogenesis. Atherogenesis is increasingly understood to
be a slowly occurring chronic inﬂammatory process.22 The
COPART Risk Score, however, takes a major CRP increase of
> 70 mg/L into account. Thereby, the detection of inﬂam-
mation in the context of PAOD in Rutherford Stages 5 and 6
needs to be considered. These stages, as is commonly
known, usually have the poorest prognosis. The present
cohort, however, only included patients in Rutherford
Stages 2 and 3. Therefore, this parameter did not differ
signiﬁcantly between the three risk groups.
This also applied to the combined continuous medication
with antiplatelet agents, statins and RAS inhibitors, which
again did not differ signiﬁcantly among the three groups.
This is mainly attributable to the small group sizes as a
limiting factor, as numerous studies have already shown
survival beneﬁts from these medications.23,24 Full compli-
ance with the drug combination of antiplatelet agents,
statins, and RAS inhibitors could only be veriﬁed in 18.6% of
patients making medication the weakest link of the COPART
Risk Score. Furthermore, this parameter reﬂects on the
enthusiasm of the primary care physician rather than the
vascular specialist. Further survival analysis without taking
the increase in CRP and medication into account did not
change the results signiﬁcantly. It could be shown that valid
mortality results could still be predicted without knowledge
of the medication. Because of this simpliﬁcation, the score
could be used more widely for mortality prediction in
claudicants.
Interestingly, the mortality differences between the LR
and MR groups only became clear in the longer term, as at
the start of the observation period the MR group had high
excess mortality compared with the LR group. Similar
overlaps between the curves also applied to the CV events,
especially in the ﬁrst half of the observation period.
Overall for the present cohort, the combination of the
COPART Risk Score variables is nonetheless a suitable tool
for predicting CV events, all cause mortality, and CV mor-
tality in claudicants before their ﬁrst peripheral endovas-
cular intervention despite the poor 5 year mortality
prediction between the LR and MR groups.
As a consequence of his study, the COPART risk score
could potentially detect patients who would beneﬁt from
more intensive CV risk factor management during their
follow up, for example, the aggressive reduction of low-
density lipoprotein (LDL) to target values below 70 mg/dL.
HR patients could also be potential candidates for the
promising PCSK9 inhibitors in order to achieve LDL reduc-
tion.25 Supervised exercise could also achieve a further
reduction of mortality, particularly in the HR group, as
claudicants would be the ideal cohort for this type of
therapy.26 Providing the calculated prognosis in the
discharge letter after the ﬁrst endovascular recanalizationmight help to minimise poor management of CV risk factors
in PAOD patients by primary care physicians.27e30 Further-
more, closer control of coexistent CAD or cerebrovascular
disease would help to achieve a reduction of mortality.
The present study has some limitations. It is a single
center study with small numbers. For testing scoring sys-
tems in particular, statistical limitations are likely. Further
studies with larger numbers are needed for more general
conclusions. Moreover, long-term results of the COPART
Risk Score for surgically treated patients would allow
comparisons between the two treatment techniques. This
could potentially create an instrument that supports the
decision making process with regards to revascularization
strategies in relation to the prognosis, and help to assess
which patients would proﬁt from more or less invasive
therapies.
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